Skip to main content

View full-text article in PMC

. 2017 Jul 3;102(9):3480–3490. doi: 10.1210/jc.2017-00558

Table 1.

Time Course of Total IGF-1, IGF-1 Bioactivity, IGFBP-1, IGFBP-2, IGFBP-3, and GH in Lean Participants, Patients With T1DM, and Obese Participants

Variable	Measurement Point (min)
Variable	Baseline	60	120	180	240
IGF-1 (µg/L)
LP	181 ± 12.9	178.7 ± 11.9	178.2 ± 12.9	174.7 ± 12.4	173.7 ± 10.5
T1DM	162 ± 16.4	156 ± 14.8	161 ± 17.2	155 ± 14.6	160 ± 15.1
OP	175 ± 14.3	174 ± 14.6	170 ± 14.4	174 ± 14.1	169 ± 13.5
IGF-1 bioactivity (µg/L)
LP	2.1 ± 0.2	1.51 ± 0.18^a	1.34 ± 0.13^a	1.16 ± 0.15^a	1.27 ± 0.15^a
T1DM	1.9 ± 0.3	1.29 ± 0.18^a	1.05 ± 0.18^a	1.4 ± 0.2^a	1.59 ± 0.26
OP	2.1 ± 0.3	1.39 ± 0.15^a	1.24 ± 0.2^a	1.37 ± 0.15^a	1.62 ± 0.19
IGFBP-1 (µg/L)
LP	43.4 ± 6.4	92.2 ± 7.6^a	79.2 ± 5.1^a	36.8 ± 4	30.8 ± 5.3^a
T1DM	57.4 ± 9.9	103.2 ± 12.7^a	112.8 ± 13.6^a	63.3 ± 11.3	32.6 ± 7.3^a
OP	10.4 ± 2.4	34.2 ± 8^a	36.7 ± 6.2^a	11.2 ± 2.5	8.2 ± 1.8
IGFBP-2 (µg/L)
LP	547 ± 75	736 ± 82^a	758 ± 89^a	729 ± 76^a	667 ± 87^a
T1DM	435 ± 84	628 ± 94^a	587 ± 87^a	621 ± 98^a	552 ± 68^a
OP	223 ± 44	298 ± 56^a	278 ± 45^a	271 ± 40^a	266 ± 36
IGFBP-3 (mg/L)
LP	3.8 ± 0.1	3.6 ± 0.1	3.7 ± 0.1	3.7 ± 0.1	3.8 ± 0.1
T1DM	3.4 ± 0.2	3.3 ± 0.2	3.3 ± 0.2	3.3 ± 0.2	3.3 ± 0.2
OP	3.9 ± 0.1	3.9 ± 0.1	3.9 ± 0.1	3.9 ± 0.1	3.9 ± 0.1
GH (µg/L)
LP	1.04 ± 0.4	0.66 ± 0.2	15.6 ± 3^a	10.7 ± 2.1^a	4.1 ± 1.5
T1DM	1.2 ± 0.3	3.4 ± 0.97	16.6 ± 3.1^a	9.7 ± 2^a	1.9 ± 0.4
OP	1.1 ± 0.5	0.98 ± 0.8	6.5 ± 1.5^a	3.9 ± 1.2^a	0.7 ± 0.2

Data presented as mean ± standard error of the mean.

^{^a}

P < 0.01 compared with baseline levels.